Related Experiment Video
Updated: Aug 21, 2026

A High-throughput Cre-Lox Activated Viral Membrane Fusion Assay to Identify Inhibitors of HIV-1 Viral Membrane Fusion
Published on: August 14, 2018
Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between
Jean-François Giguère1, Michel J Tremblay
1Research Center in Infectious Diseases, RC709, CHUL Research Center and Faculty of Medicine, Laval University, Quebec, Canada G1V 4G2.
Abstract:
A variety of host factors, including membrane proteins acquired by human immunodeficiency virus type 1 (HIV-1), play a dominant role in HIV-1 adsorption onto host cells. Examples include the integrin intercellular adhesion molecule 1 (ICAM-1), which, once acquired by HIV-1, promotes virus infectivity via ligation to LFA-1. We tested the ability of statins to diminish HIV-1 replication, based on the idea that these compounds have been shown to block ICAM-1-LFA-1 interactions. Our data indicate that statins diminish HIV-1 attachment to target cells by suppressing ICAM-1-LFA-1 interactions. The capacity of statins to limit the initial steps in virus replication could represent an interesting approach for the treatment of HIV-1 infection.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Inhibitors Of Virion Release
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles

